[go: up one dir, main page]

DE69815554D1 - Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen - Google Patents

Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen

Info

Publication number
DE69815554D1
DE69815554D1 DE69815554T DE69815554T DE69815554D1 DE 69815554 D1 DE69815554 D1 DE 69815554D1 DE 69815554 T DE69815554 T DE 69815554T DE 69815554 T DE69815554 T DE 69815554T DE 69815554 D1 DE69815554 D1 DE 69815554D1
Authority
DE
Germany
Prior art keywords
antagonists
receptor
adenosine
serve
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69815554T
Other languages
English (en)
Other versions
DE69815554T2 (de
Inventor
Osamu Asano
Hitoshi Harada
Yorihisa Hoshino
Seiji Yoshikawa
Takashi Inoue
Tatsuo Horizoe
Nobuyuki Yasuda
Kaya Nagata
Junsaku Nagaoka
Manabu Murakami
Seiichi Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE69815554D1 publication Critical patent/DE69815554D1/de
Publication of DE69815554T2 publication Critical patent/DE69815554T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69815554T 1998-01-05 1998-12-24 Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen Expired - Fee Related DE69815554T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP52698 1998-01-05
JP52698 1998-01-05
PCT/JP1998/005870 WO1999035147A1 (en) 1998-01-05 1998-12-24 Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes

Publications (2)

Publication Number Publication Date
DE69815554D1 true DE69815554D1 (de) 2003-07-17
DE69815554T2 DE69815554T2 (de) 2004-05-06

Family

ID=11476226

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815554T Expired - Fee Related DE69815554T2 (de) 1998-01-05 1998-12-24 Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen

Country Status (7)

Country Link
US (2) US6579868B1 (de)
EP (2) EP1054012B1 (de)
AT (1) ATE242775T1 (de)
AU (1) AU1688599A (de)
CA (1) CA2315736A1 (de)
DE (1) DE69815554T2 (de)
WO (1) WO1999035147A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
DE19917785A1 (de) * 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
NZ521633A (en) 2000-04-26 2005-01-28 Eisai Co Ltd Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
JPWO2002079204A1 (ja) * 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
JP5280597B2 (ja) * 2001-03-30 2013-09-04 サンスター技研株式会社 一液加熱硬化型エポキシ樹脂組成物および半導体実装用アンダーフィル材
JP2005502624A (ja) * 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ITRM20010465A1 (it) 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
TWI330183B (de) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TWI301834B (en) * 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
KR20150080013A (ko) 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
JP2004018453A (ja) * 2002-06-14 2004-01-22 Sumika Fine Chemicals Co Ltd アルキニルプリン化合物およびその製造方法
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
EP1615931A1 (de) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazine und verfahren zu deren herstellung und anwendung
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1633756B1 (de) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a-adenosinrezeptorantagonisten
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7256196B1 (en) * 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US7763625B2 (en) * 2004-01-28 2010-07-27 Kyowa Hakko Kirin Co., Ltd. Agents for treating migraine
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
EP1740587A4 (de) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selektive antagonisten von a2a-adenosinrezeptoren
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007020853A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP1852108A1 (de) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
AU2008215490A1 (en) * 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
WO2008128191A2 (en) * 2007-04-13 2008-10-23 Chemgenex Pharmaceuticals, Inc. Oral cephalotaxine dosage forms
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2010106145A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CN103261200B (zh) * 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
CA2864499C (en) * 2012-02-17 2020-03-31 Research Triangle Institute Peripherally restricted diphenyl purine derivatives
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN107613769A (zh) 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
US10703755B2 (en) 2016-04-26 2020-07-07 Sumitomo Dainippon Pharma Co., Ltd. Substituted purine derivative
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
SG11202000823WA (en) 2017-08-01 2020-02-27 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
IL272637B2 (en) 2017-08-21 2024-03-01 Merck Patent Gmbh History of benzaimidazole, their preparation and medicines containing them
CA3073343A1 (en) 2017-08-21 2019-02-28 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
ES2960883T3 (es) 2018-10-25 2024-03-07 Merck Patent Gmbh Derivados de 5-azaindazol como antagonistas de los receptores de adenosina
JP7551607B2 (ja) 2018-10-25 2024-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176470T1 (de) 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk Xanthinderivate
US5256398A (en) 1990-11-08 1993-10-26 Whitby Research, Inc. Composition for determining viability of tissue
GB9125002D0 (en) * 1991-11-25 1992-01-22 Ici Plc Azole derivatives
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
JPH11508267A (ja) * 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
DE19541264A1 (de) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
CA2257222C (en) * 1996-06-06 2002-08-20 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
US6511984B2 (en) * 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists

Also Published As

Publication number Publication date
EP1054012A4 (de) 2001-12-12
AU1688599A (en) 1999-07-26
US6579868B1 (en) 2003-06-17
ATE242775T1 (de) 2003-06-15
EP1300147A1 (de) 2003-04-09
DE69815554T2 (de) 2004-05-06
USRE39112E1 (en) 2006-05-30
WO1999035147A1 (en) 1999-07-15
EP1054012B1 (de) 2003-06-11
EP1054012A1 (de) 2000-11-22
CA2315736A1 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
DE69815554D1 (de) Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
BR0207658A (pt) Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
BRPI0416605A (pt) composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
IL186200A (en) Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
BR0211550A (pt) Derivados de triazolil-imidazopiridina e das triazolilpurinas úteis como ligandos do receptor a2a da adenosina, e seu uso como medicamentos
UA94913C2 (ru) Применение эритропоэтина для лечения сахарного диабета
WO2003080582A3 (de) Fredericamycin-derivate
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
PE20110396A1 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
EP1845095A4 (de) 1-thio-d-glucitolderivate
BRPI0409078A (pt) composto, métodos para o tratamento ou prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, para o tratamento ou prevenção de obesidade, para o tratamento ou prevenção de um distúrbio relacionado com a obesidade, para o tratamento ou prevenção de diabete melito, para o tratamento ou prevenção da disfunção sexual masculina ou feminina e para o tratamento ou prevenção de disfunção erétil, composição farmacêutica, métodos para o tratamento de disfução erétil em um mamìfero, para o tratamento de diabete em um mamìfero e para o tratamento de obesidade em um mamìfero, e, uso de um composto
BR0011891A (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
BR0312169A (pt) Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação
NO20082445L (no) Neuropeptid-2 reseptor-agonister
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
TW200745037A (en) Organic compounds
NO980273L (no) Femleddede heterocykluser med bifenylsulfonylsubstitusjon fremgangsmÕte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
BR9917005A (pt) Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
BR0315082A (pt) Preparação sólida
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee